Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

MLA

Ott, Patrick A., et al. “Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 22, Aug. 2017, pp. 2535–41. EBSCOhost, https://doi.org/10.1200/JCO.2017.72.5952.

APA

Ott, P. A., Bang, Y.-J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M., & Soria, J.-C. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(22), 2535–2541. https://doi.org/10.1200/JCO.2017.72.5952

Chicago

Ott, Patrick A, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J Pishvaian, Hope S Rugo, Igor Puzanov, et al. 2017. “Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35 (22): 2535–41. doi:10.1200/JCO.2017.72.5952.